Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer.
Ayumi HashimotoDebashis SarkerVikash ReebyeSheba JarvisMikael H SodergrenAndrew KossenkovEmilio SansevieroNina RaulfJenni VasaraPinelopi AndrikakouTim MeyerKai-Wen HuangRuth PlummerCheng Ean CheeDuncan SpaldingMadhava PaiShahid KhanDavid J PinatoRohini SharmaBristi BasuDaniel PalmerYuk-Ting MaJeff EvansRobert HabibAnna MartirosyanNaouel ElasriAdeline ReynaudJohn J RossiMark CobboldNagy A HabibDmitry I GabrilovichPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
This report demonstrates that therapeutic upregulation of the transcription factor C/EBPα causes inactivation of immune-suppressive myeloid cells with potent antitumor responses across different tumor models and in cancer patients. MTL-CEBPA is currently being investigated in combination with pembrolizumab in a phase I/Ib multicenter clinical study (NCT04105335).